Kura Oncology vs Nuvation Bio
KURA and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KURA and NUVB compare
Nuvation Bio is the larger company, worth 2.1 times as much as Kura Oncology ($1.4B against $666M).
Nuvation Bio keeps more of each dollar of sales as profit, with a net margin of −88.2% compared with −369% at Kura Oncology.
Nuvation Bio scores higher on the StockData Score (4 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KURA | NUVB |
|---|---|---|
| Size and price | ||
| Market cap | $666M | $1.4B |
| Share price | $7.49 | $3.90 |
| Change, 1 year | −33.2% | −19.8% |
| Change, 5 years | −46.5% | −52.3% |
| Beta (5Y) | 2.30 | 1.77 |
| Employees | 260 | 298 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.4× | 8.1× (better) |
| P/B | 37.1× | 5.4× (better) |
| FCF yield | −13.4% | – |
| Fair value | – | $1.89 |
| Margin of safety | – | −107% |
| Growth | ||
| Revenue growth (TTM) | – | 1084% |
| Profitability | ||
| Operating margin | −394% | −81.0% (better) |
| Net margin | −369% | −88.2% (better) |
| FCF margin | −112% | – |
| Return on equity | −225% | −47.8% (better) |
| Financial health | ||
| Debt / equity | 0.55 | 0.02 (better) |
| Interest coverage | −227.1× | −5.4× (better) |
| Current ratio | 3.60 | 8.37 (better) |
| Altman Z-score | −3.56 | 0.12 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 98.0% | 66.5% |
| Held by insiders | 2.7% | 24.6% |
| Insider net buying, 12 months | $512K (better) | −$4.5M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 14.6% | 23.4% |
Go deeper
- KURA stock overview
- KURA income statement
- KURA valuation and score
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.